BOCH
CMPX icon

Blue Owl Capital Holdings’s Compass Therapeutics CMPX Stock Holding History

Blue Owl Capital Holdings’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$106K Sell
303,800
-96,200
-24% -$284K 0.02% 49
2026
Q1 		$500K Buy
+400,000
New +$2.31M 0.13% 42

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Blue Owl Capital Holdings's CMPX Position: Q2 2026 in Review

Blue Owl Capital Holdings increased its Compass Therapeutics (CMPX) stake by 23% in Q2 2026, buying an estimated $2.02M and bringing the position to 3,624,076 shares worth $7.94M. The position accounts for 1.19% of the portfolio, ranked #16.

Blue Owl Capital Holdings first reported a position in CMPX in Q4 2023 and has held it in 11 quarters since. The position peaked at $18.6M in Q4 2025. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Blue Owl Capital Holdings held 3,624,076 shares of Compass Therapeutics worth $7.94M as of Q2 2026.
  • Blue Owl Capital Holdings bought 682,551 Compass Therapeutics shares in Q2 2026, an estimated $2.02M.
  • Compass Therapeutics made up 1.19% of Blue Owl Capital Holdings's portfolio in Q2 2026, its #16 holding.
  • Blue Owl Capital Holdings first reported a position in Compass Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Blue Owl Capital Holdings's Compass Therapeutics position peaked at $18.6M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Blue Owl Capital Holdings's 13F filing for Q2 2026, filed 11 Aug 2026.